	US 12,263,146 B2
	Non-linear dosing of mirdametinib
Uchenna H. Iloeje, Stamford, CT (US); Abraham J. Langseth, Stamford, CT (US); and Todd Shearer, Stamford, CT (US)
Assigned to SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US)
Filed by SpringWorks Therapeutics Inc., Stamford, CT (US)
Filed on Aug. 2, 2023, as Appl. No. 18/364,058.
Application 18/364,058 is a continuation of application No. 18/185,045, filed on Mar. 16, 2023, granted, now 11,806,321.
Claims priority of provisional application 63/321,036, filed on Mar. 17, 2022.
Claims priority of provisional application 63/321,046, filed on Mar. 17, 2022.
Prior Publication US 2024/0000731 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/166 (2006.01); A61K 9/00 (2006.01); A61K 31/216 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61K 31/216 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)]

15 Claims

1. A method of treating a human patient 2 years or older who has neurofibromatosis type 1 (NF1) associated inoperable plexiform neurofibromas (PN) and a body surface area of 1.5 to 1.74 m²comprising orally administering an effective amount of mirdametinib to the patient, wherein the patient is initially administered 4 mg mirdametinib twice daily.